SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following reports that the company is preparing an offer to acquire eBay, fueling investor speculation about a potential strategic pivot into a larger e-commerce marketplace. While the community is debating the feasibility and financing of such a large-scale acquisition, many are focused on the potential for a short squeeze and the stock's significant move on high volume.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing intense momentum as traders speculate on a potential short squeeze, driven by a high short interest, significant cost-to-borrow fees, and a scarcity of available shares. The community is actively discussing the stock's potential to rally further ahead of upcoming earnings, with many users advocating for a 'diamond hands' strategy to pressure short sellers into covering their positions.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS Tech Inc. is generating significant buzz due to its low-float profile and extreme price volatility, which has led to intense speculation about potential short squeezes. Community discussions are heavily focused on the stock's recent performance following a reverse split, with traders debating whether the movement is a genuine breakout or a classic pump-and-dump setup.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilio shares are rallying following the company's inclusion in the S&P MidCap 400 index, a move that has sparked renewed momentum among investors. Community sentiment is shifting toward optimism, with many highlighting potential AI-driven voice demand and operational discipline as foundational strengths for the stock's future performance.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2025 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is trending as the market reacts to strong box office momentum from the Michael Jackson biopic, fueling investor sentiment around the company's standalone studio potential. Community discussions are heavily focused on the stock's role as a high-conviction buyout candidate, with participants tracking significant institutional accumulation and strategic board moves as potential indicators of an upcoming acquisition.

Dogelon Mars

Dogelon Mars is trending amid persistent community speculation regarding potential token burns and future utility, with holders actively debating whether the project's historical ties to Elon Musk and low market cap offer a contrarian opportunity. While sentiment remains highly polarized between long-term supporters hoping for a resurgence and critics labeling the asset a legacy pump-and-dump, the community continues to mobilize around high-visibility social media activity to drive momentum.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending as investors show strong enthusiasm following the "Best New Drug" award for Revuforj and anticipation for key data presentations at the upcoming ASH meeting. The community is actively discussing a potential buyout by Incyte due to strategic synergies, with many highlighting the stock's significant upside potential relative to its current valuation and high short interest.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as investors weigh strong commercial launch momentum for TONMYA against concerns over proposed corporate governance measures, including authorization for future reverse stock splits. The community is actively debating the company's long-term capital strategy versus the potential for clinical success in the fibromyalgia market.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors digest the recent energization of the Sweetwater 1 substation while speculating on future hyperscaler deal flow ahead of upcoming earnings. Community sentiment remains polarized, with many debating the company's execution speed versus the recent decline in share price and ongoing retail frustrations over the timing of corporate communications.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors react to conservative 2026 financial guidance and the anticipated impact of the TDAPA reimbursement transition, sparking heated community debate over the company's valuation versus its long-term growth potential. While some shareholders are expressing frustration over the recent stock performance and leadership communication, others are actively focused on the upcoming Phase 3 trial results for REZZAYO and ongoing legislative efforts to secure long-term reimbursement for DefenCath.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company stated that its trial demonstrated that 55% of the patients showed a 30% or greater reduction in lesion size compared to the control group.</li><li>Ocugen also noted a 27% slower rate of damage to important eye cells, which is linked to better vision.</li><li>The company also added that a subgroup analysis showed a 33% reduction in lesion growth compared to the control group in the medium-dose OCU410, while similar reductions were observed in the high-dose group.</li></ul>Ocugen Inc. (OCGN) shares tanked more than 13% in Tuesday’s opening trade after the company announced an update in its gene therapy trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).Ocugen said 12-month Phase 2 trial data showed its drug OCU410 significantly reduced lesion growth at the dose planned for Phase 3.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/OCGN">Ocugen</a> trended in the ‘neutral’ territory, with message volumes at ‘high’ levels.<h2 class="st-heading-2">What Did Ocugen Announce?</h2>Ocugen stated that its trial demonstrated that 55% of the patients in the study showed a reduction of 30% or more in the lesion size when compared to the control group. The company also noted that there was a 27% slower rate of damage to important eye cells, which is linked to better vision.Ocugen also added that a subgroup analysis showed 33% reduction in lesion growth compared to the control group in medium dose OCU410, while similar reductions were observed in the high dose group.“We have confirmed robust treatment effect from a well-controlled Phase 2 trial of a genetic medicine for GA. Now we can move on to Phase 3 with a high degree of confidence,” said Ocugen CEO Shankar Musunuri.The company stated that the global prevalence of dAMD is 266 million, while GA affects approximately up to three million people in the U.S. and Europe. The company says this number is expected to increase significantly as populations age.GA is an advanced stage of dAMD marked by progressive damage to the macula, resulting in permanent loss of central vision.Ocugen said that there were no OCU410-related serious adverse events observed in the Phase 2 trial. It also said that there were no cases of endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ischemic optic neuropathy reported to date.<h2 class="st-heading-2">What Does Ocugen Do?</h2>Ocugen is a Malvern, Pennsylvania-based biotechnology company that is developing novel gene therapies to address major blindness diseases.OCU410 is an investigational gene therapy injected under the retina that delivers RORA, a protein that controls key pathways involved in protecting and maintaining the retina.<a href="https://stocktwits.com/symbol/OCGN">OCGN stock</a> is up 36% year-to-date and 187% over the past 12 months. The S&amp;P Kensho New Economies Composite ETF (KOMP) is up 21% over the past 12 months, while the Vanguard Health Care Index Fund ETF Shares (VHT) is down 1%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-li-stock-rising-today/cZ3nKYIRIKv">China’s Tesla Rival Li Auto Announces $1 Share Repurchase Program — LI Stock Gains</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of US biotechnology company Ocugen Inc is displayed on a smartphone

OCGN Stock Tanks After Gene Therapy Trial Update — What Did Ocugen Announce?

Ocugen said 12-month Phase 2 trial data showed its drug OCU410 significantly reduced lesion growth at the dose planned for Phase 3.

Equity

<ul class="summary-bullets"><li>The company stated in its announcement that it intends to use the funds raised through this stock offering to acquire additional inventory, for working capital needs, and for general corporate purposes.</li><li>Donald Trump Jr., who is on the company’s advisory board, said that the latest capital infusion will enable Unusual Machines to build the foundation for a strong domestic drone industry.</li><li>The Florida-based company announced a public offering on Thursday to expand its U.S. drone parts inventory and for working capital and general corporate purposes.</li></ul>Unusual Machines Inc. (UMAC) on Friday announced the pricing of its public offering to raise $150 million, which includes a strategic investment from Ondas Inc. (ONDS).Unusual Machines stated that it will issue 8.8 million shares at $17 apiece, a discount of more than 9% to the stock’s closing price on Thursday.<a href="https://stocktwits.com/symbol/UMAC">Unusual Machines shares</a> were down more than 13% in Friday’s opening trade. Retail sentiment on Stocktwits about the company trended in ‘bearish’ territory, while message volume was at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Will UMAC Use These Funds For?</h2>Unusual Machines stated in its announcement that it intends to use the funds raised through this stock offering to acquire additional inventory, for working capital needs, and for general corporate purposes.“We approach capital the same way we approach operations, deliberately and with a clear plan for deployment. This raise allows us to expand inventory, support production, and continue building a reliable, U.S.-based supply chain for drone components,” said Unusual Machines CEO Allan Evans.President Donald Trump’s son, Donald Trump Jr., who is on the company’s advisory board, said that the latest capital infusion will enable Unusual Machines to build the foundation for a strong domestic drone industry.<h2 class="st-heading-2">What Does Unusual Machines Do?</h2>Unusual Machines manufactures and sells drone components and drones. It also sells small acrobatic first-person-view (FPV) drones and equipment directly to consumers.The Florida-based company announced a public offering on Thursday to expand its U.S. drone parts inventory and for working capital and general corporate purposes.<a href="https://stocktwits.com/symbol/UMAC">UMAC stock</a> is up 127% year-to-date, while ONDS stock is up 4%. The SPDR S&amp;P Kensho New Economies Composite ETF (KOMP) is up 23% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 35%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fedex-beat-and-raise-q3-wall-street-price-target-hikes-for-fdx-stock/cZ3Xqp2RILh">FedEx's Beat And Raise Q3 Earns Street Accolades As Price Target Hikes Pour In — Analysts Flag 'Unique Combination' Of Price And Yield Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Is UMAC Stock Falling Today?

Unusual Machines stated that it will issue 8.8 million shares at $17 apiece, a discount of more than 9% to the stock’s closing price on Thursday.

<ul class="summary-bullets"><li>RCAT reported Q4 total revenue of $26.2 million, representing an increase of 1,985% or $24.9 million from $1.3 million in the prior year.</li><li>Red Cat’s full-year 2025 total revenue was $40.7 million, representing an increase of 161%, from the year-ago period.&nbsp;</li></ul>Red Cat Holdings (<a href="https://stocktwits.com/symbol/RCAT">RCAT</a>) stock fell nearly 5% in extended hours of trading on Wednesday despite reporting&nbsp;a nearly 2,000% jump in its fourth quarter (Q4) revenue.&nbsp;RCAT reported Q4 total revenue&nbsp;of $26.2 million, up 1,985% or $24.9 million, compared to $1.3 million of revenue in the prior year. It was above analyst expectations of $23.9 million, according to Stocktwits data.The company’s net loss per share of $0.17 during the quarter was&nbsp;narrower than $0.33 loss per share from the year-ago quarter. However,&nbsp;analysts had estimated a loss per share of $0.15.&nbsp;<h2 class="st-heading-2">Leadership Take</h2>“2025 was a transformative year for Red Cat as we strengthened our position as a trusted provider of advanced drone solutions for defense and government customers,” said Jeff Thompson, CEO of Red Cat.&nbsp;“We delivered year-over-year revenue growth of 161%, launched our FANG™ FPV platform, and expanded our Army relationship, and received our first order for 100 Black Widows through the NSPA - a major milestone that underscores growing international demand for our products," Thompson added.During fiscal year 2025, Red Cat, across divisions, expanded its maritime division, BlueOps to 166,000 sq. ft., its VTOL drone, sensor and software solutions division FlightWave to 51,000 sq. ft., and Teal drones&nbsp;division to 37,000 sq. ft. Red Cat achieved a total capacity of 2,54,000 sq. ft. as of Dec. 31, 2025.&nbsp;Red Cat’s full-year 2025 revenue was $40.7 million, representing an increase of 161% or $25.1 million from $15.6 million in the prior year, according to the statement.&nbsp;<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around RCAT stock trended in the ‘bearish’ territory amid ‘low’ message volume.One bearish user predicted that RCAT’s stock will go under $15.&nbsp;<stembedurl>https://stocktwits.com/CashCows_/message/647923045</stembedurl>Shares in the company have risen 106% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Red Cat Holdings, Inc. is displayed on a smartphone screen.

Red Cat Stock Slips As Q4 Loss Misses Estimates

The company’s net loss per share of $0.17 during the quarter missed analysts’ estimate of loss per share of $0.15. 

<ul class="summary-bullets"><li>DLocal said that it expects FY26 TPV to increase by up to 60% and gross profit to rise in the range of 22.5% – 27.5% compared to 2025.&nbsp;</li><li>DLocal’s Q4 revenues amounted to $337.9 million, up 65% year-over-year.</li><li>The company said that the board authorized a new share repurchase program to purchase up to $300 million of Class A common shares.&nbsp;</li></ul>Shares of dLocal (<a href="https://stocktwits.com/symbol/DLO">DLO</a>) jumped 5% during extended hours of trading on Wednesday after it reported&nbsp;a jump in its fourth-quarter (Q4) revenue as payments volume hit record during the quarter.&nbsp;DLocal’s Q4 revenues amounted to $337.9 million, up 65% year-over-year compared to $204.5 million in the fourth quarter of 2024. It also sailed past analyst expectations of $296.3 million, according to Stocktwits.&nbsp;The company's&nbsp;net income for Q4 2025 was $55.6 million, or $0.18 per diluted share, up 87% compared to a profit of $29.7 million, or $0.10 per diluted share, for the fourth quarter of 2024.&nbsp;“2025 was a year of exceptional execution, one that proved the strength of our business as we continue to build a world-leading financial infrastructure platform for emerging markets. Our flywheel is accelerating: high growth in a massive and expanding TAM, strong customer loyalty and retention, a growing capacity to innovate, and an asset-light, high-cash-conversion financial model,” said Pedro Arnt, CEO of dLocal.DLO’s Total Payment Volume (TPV) reached a record $13.1 billion in the quarter, up 70% year-over-year compared to $7.7 billion in the fourth quarter of 2024.&nbsp;<h2 class="st-heading-2">Outlook And Buyback</h2>DLocal said that it expects FY26 TPV to increase by up to 60% and gross profit to rise in the range of 22.5% – 27.5% compared to 2025.&nbsp;The company said that the&nbsp;board authorized a new share repurchase program to purchase up to $300 million of Class A common shares, expiring at the earliest of March 2027 or upon reaching the repurchase limit.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around DLO stock trended in the ‘bullish’ territory amid ‘normal’ message volume.Shares in the company fell nearly 20% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

dLocal said that the board authorized a new share repurchase program to purchase up to $300 million of Class A common shares. 

Why Did DLO Stock Jump After-Hours Today?

DLO’s Total Payment Volume reached a record $13.1 billion in the fourth quarter, up 70% year-over-year. 

Eastman Kodak’s shares rallied nearly 12% in extended hours of trading on Thursday after it reported strong growth in its fourth-quarter revenue.&nbsp;Kodak reported consolidated revenues of $290 million in the fourth quarter of 2025, compared with $266 million in the year-ago period, an increase of $24 million or 9%. The rise in revenue was driven by strong performance in Advanced Materials &amp; Chemicals (AM&amp;C) and Print segments.&nbsp;“Kodak ended 2025 with a strong fourth quarter, which has created a foundation for growth in 2026,” said Jim Continenza, Kodak’s Executive Chairman and CEO. “We continue to execute the long-term plan we began in 2019, which focuses on de-levering the company while continuing to invest in our infrastructure and new product innovation”.&nbsp;Kodak ended the year with a cash balance of $337 million, an increase of $136 million from December 31, 2024. The increase was primarily due to the net impact of the Kodak Retirement Income Plan (KRIP) termination and reversion of assets to the company of $153 million.The company reported GAAP net loss of $108 million in Q4 2025, compared with net income of $26 million for Q4 2024. The decline in net income was primarily due to the non-recurring impact of the Kodak Retirement Income Plan ("KRIP") termination and excise tax paid on the reversion of assets to the company.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around KODK stock trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;One user on Stocktwits called the share rise ‘better than expected’.<stembedurl>https://stocktwits.com/PharmGal/message/647406000</stembedurl>A bullish user said they are optimistic for Kodak in 2026.&nbsp;<stembedurl>https://stocktwits.com/NikkyBenz13/message/647405165</stembedurl>Another bullish user opined that continued growth in Kodak’s Advanced Materials &amp; Chemicals is especially encouraging and could open doors to new markets.&nbsp;<stembedurl>https://stocktwits.com/Judykay/message/647399877</stembedurl>Shares in the company are down 9.4% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the Eastman Kodak Company logo is seen displayed on a smartphone screen.

Eastman Kodak Stock Rallies After-Hours As Q4 Revenue Jumps On Strong Segment Performance

Kodak reported consolidated revenues of $290 million in the fourth quarter of 2025, compared with $266 million in the year-ago period, an increase of $24 million or 9%.

<ul class="summary-bullets"><li>Gorilla Technology Group posted adjusted basic earnings per share of $0.89 for the year, beating Wall Street expectations of $0.84 per share.&nbsp;</li><li>The company said that in the first two months of 2026, it had collected over $22 million from its largest customers as payment for solutions delivered and invoiced in 2025.&nbsp;</li><li>Gorilla Technology also said that its pipeline at present was more than $7 billion, expanded due to advanced-stage AI and GPU infrastructure opportunities in Saudi Arabia, Thailand, Indonesia, India, and Malaysia.</li></ul>Shares of Gorilla Technology Group Inc. gained more than 0.6% in Monday’s extended trading hours after closing 5.41% higher. The company reported record revenue and profitability for the full year 2025.Revenue for the year ended Dec. 31, 2025, grew 35.7% to $101.4 million, with annual revenue exceeding $100 million for the first time in the company’s history. Analysts on average expected the company to post revenue of $99.68 million for the year, as per data from Fiscal.ai.Meanwhile, Gorilla Technology Group (GRRR) posted adjusted basic earnings per share of $0.89 for the year, beating Wall Street expectations of $0.84 per share.“Our 2025 results are built on delivered work, disciplined cost control, and improved quality of earnings. We are not managing for optics, instead, we are managing for execution,” said Jay Chandan, Chairman and CEO of the company.<h2 class="st-heading-2">2026 Position</h2>Gorilla Technology said that in the first two months of 2026, it had collected over $22 million from its largest customers as payment for solutions delivered and invoiced in 2025. The company also said that additional collections were slated for the coming weeks, which would further support liquidity, working capital discipline, and execution across active programmes.As of Feb. 26, 2026, the company had $108.4 million of unrestricted cash and $116.6 million of total cash.Gorilla Technology also said that its pipeline at present was more than $7 billion, expanded due to advanced-stage AI and GPU infrastructure opportunities in Saudi Arabia, Thailand, Indonesia, India, and Malaysia.“We are expanding our evaluation work in India and progressing our strategy in the Middle East, which includes Saudi Arabia where an MoU has been signed and we are actively exploring data centre development opportunities. We are also exploring opportunities to buy and / or build our own data centre assets. Ownership changes the model: more control over delivery, stronger long-term positioning and the potential to build recurring infrastructure-led revenue streams rather than relying only on project cycles,” Chandan said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GRRR">GRRR shares</a> jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours. Meanwhile, message volumes surged from ‘low’ to ‘high’ levels.One bullish user praised the company’s results, saying the stock was ‘very cheap’.<stembedurl>https://stocktwits.com/ceonner/message/646366647</stembedurl>&nbsp;Another user cited the company’s strong cash position, near zero-debt, strong revenue growth, expansion, and projects to say the company was ‘way undervalued’.<stembedurl>https://stocktwits.com/Creyedr/message/646370025</stembedurl>&nbsp;Shares of GRRR have declined more than 61% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gorilla Technology logo is seen displayed on a smartphone screen. 

GRRR Shares Gain After-Hours On Breaching $100M Annual Revenue Mark — Retail Says Stock ‘Very Cheap’ 

Revenue for the year ended Dec. 31, 2025, grew 35.7% to $101.4 million, compared to analysts’ expectations of $99.68 million in revenue. 

<ul class="summary-bullets"><li>uniQure added that the FDA has recommended that the company conduct a prospective, randomized, double-blind, sham-surgery-controlled study.</li><li>The company stated that it intends to continue engaging with the FDA regarding Phase III trial development.</li><li>uniQure added that it plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.</li></ul>uniQure NV (QURE) shares plunged by nearly 45% in Monday’s pre-market trade after the company issued an update about its investigational gene therapy for Huntington’s disease (HD).uniQure said the FDA does not agree that Phase I/II data, compared with an external control, are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.“While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA’s stated commitment to regulatory flexibility may be appropriately applied in this setting,” said uniQure CEO Matt Kapusta.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/QURE">uniQure</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels.<h2 class="st-heading-2">FDA Urges Sham-Controlled Trial</h2>uniQure added that the FDA has recommended that the company conduct a prospective, randomized, double-blind, sham-surgery-controlled study.The company stated that it intends to continue engaging with the FDA regarding Phase III trial development. uniQure added that it plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.“We remain committed to engaging with the FDA to determine a clear, scientifically grounded, and efficient path forward for AMT-130,” Kapusta added.<h2 class="st-heading-2">uniQure’s Gene Therapy Pipeline</h2>uniQure currently has six gene therapies in its pipeline, each at different stages of progress and approvals.The company’s Hemophilia B gene therapy, AMT-061, has already been approved, and the AMT-130 therapy for Huntington’s disease is currently at the most advanced stage of trials.uniQure’s other gene therapies include treatments for Fabry disease, Amyotrophic Lateral Sclerosis, and Temporal Lobe Epilepsy, apart from other undisclosed programs.<a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down 35% year-to-date, but up 29% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-aes-stock-falling-today-blackrock-gip-eqt-deal/cZd3EuiRIcw">Why Is AES Stock Falling Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did QURE Stock Almost Halve Pre-Market Today?

uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did NGNE Stock Surge 25% In Pre-Market Today?

The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target 

<ul class="summary-bullets"><li>Aspen posted a net loss of $72.9 million, or $0.88 per share, compared with net income of $11.4 million last year.</li><li>The company launched a strategic review to strengthen its long-term positioning.</li><li>Aspen forecast revenue of $35 million to $40 million and net loss of $20 million to $23 million for Q1 FY26.&nbsp;</li></ul>Shares of Aspen Aerogels (ASPN) slumped 25% on Wednesday, after the company reported a sharp decline in fourth-quarter results and launched a strategic review to strengthen its long-term positioning.<a href="https://stocktwits.com/symbol/ASPN">ASPN shares</a> were trading at their lowest levels since April 2019.Fourth-quarter (Q4) revenue crashed 66% to $41.3 million, pressured by weaker demand across Thermal Barriers and Energy Industrials business segments. Analysts, on average, had expected a revenue of $44.3 million, according to Fiscal.ai data.Aspen posted a net loss of $72.9 million, or $0.88 per share, compared with net income of $11.4 million last year. The company said that its bottom line was impacted by restructuring, asset impairment, and other one-time charges. Excluding these items, adjusted net loss was $27.7 million, or $0.34 per share.<h2 class="st-heading-2">Strategic Review To Enhance Long-Term Prospects</h2>Aspen also launched a strategic review to strengthen its long-term positioning, it said. As part of the process, the company will evaluate a wide range of strategic alternatives to ensure it is properly structured. To support the review, Aspen appointed Piper Sandler &amp; Co. as its exclusive financial advisor.“Our focus is clear — to ensure the company’s strategy, capital allocation, and asset base are aligned to maximize value creation,” said Don Young, President and CEO.For the first quarter of 2026, the company forecast revenue of $35 million to $40 million and a net loss of $20 million to $23 million.&nbsp;The company confirmed that its Q4 2025 EV customer award is for Volvo Cars. In the previous quarter, Aspen was also awarded a North Sea subsea pipeline project, with delivery expected in Q3 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits shifted to ‘neutral’ from ‘bullish’ a day earlier, amid ‘high’ message volumes.One user said the company’s outlook is expected to improve after the first quarter.<stembedurl>https://stocktwits.com/CFAstockpicker/message/645856091</stembedurl>Year-to-date, the stock has declined 7%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Aspen Aerogels Inc. (Photo illustration by Cheng Xin/Getty Images)

Why Did ASPN Stock Plummet 25% Today?

The company reported a 66% decline in Q4 revenue to $41.3 million, which fell short of Street expectations.

<ul class="summary-bullets"><li>Deployment comes amid heightened concern over drone activity in Germany.</li><li>Last week, Ondas said that its subsidiary, Airobotics, has received a new multi-million-dollar order from a major European customer in a NATO country for its Iron Drone Raider counter-UAS system.</li><li>Ondas Holdings’ subsidiary 4M Defense was also recently awarded a large-scale multi-year demining program in Israel after winning a competitive tender valued at over $30 million.&nbsp;</li></ul>Ondas Holdings shares jumped 9% on Tuesday after it announced that its subsidiary Sentrycs has successfully delivered and deployed its C-UAS solutions to a German State Police office.This deployment comes amid heightened concern over drone activity in Germany, with more than 1,000 suspicious flights reported by the federal criminal police (BKA) in 2025 - including incidents near military facilities, airports, and sensitive government zones, the company said in a statement.&nbsp;"Our deployment with the German State Police demonstrates the immediate impact of lawful, precise drone mitigation. With the launch of our new man-carried solution, Sentrycs Scout, we're extending that capability to tactical units that require mobility without compromising performance," said Tal Cohen, CEO of Sentrycs.&nbsp;<h2 class="st-heading-2">New Foreign Contracts</h2>Last week, Ondas said that its subsidiary, Airobotics, has received a new multi-million-dollar order from a major European customer in a NATO country for its Iron Drone Raider counter-UAS system.The order followed Ondas' operational deployment of the system at a major European international airport, part of a separate contract from the same customer, it said.&nbsp;The Iron Drone Raider order is part of a previously signed $16.8 million order that was given to ONDAS to protect two major European international airports.&nbsp;The new contract award is focused on defending critical assets in complex civil environments, an area where Iron Drone Raider delivers a uniquely differentiated capability.Ondas Holdings’ subsidiary 4M Defense was also recently awarded a large-scale multi-year demining program in Israel after winning a competitive tender valued at over $30 million.&nbsp;The project covers approximately 741 acres of historically contaminated and strategically sensitive terrain along the Israel-Syria border, representing one of the largest land-clearance efforts ever undertaken in the country, with an initial execution period of up to three years and options for extensions and scope expansion beyond the original contract.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around ONDS trended in ‘bearish’ territory amid ‘low’ message volume.&nbsp;Shares in the company have risen more than 400% over the past year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/microcap-stock-sgn-shoots-up-50-percent-today/cZRWs7QR4uU">Microcap Stock SGN Shoots Up 50% Today – What Is Making Traders Bullish On The Stock?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ondas Holdings logo is seen displayed on a smartphone screen.

Ondas Holdings’ Stock Is Rallying Again Today – What’s The Reason Behind It

Ondas said that its subsidiary Sentrycs has successfully delivered and deployed its C-UAS solutions to a German State Police office.

KOMP
SPDR S&P Kensho New Economies Composite ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest KOMP News

KOMPSPDR S&P Kensho New Economies Composite ETF